Skip to Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Radiation Research Program
Contact NExT
Show menu
Search this site
Last Updated: 06/22/20

Preclinical Chemo-Radiotherapy Testing Consortium

PCRTC U01 Program

Introduction

The Preclinical Chemo-Radiotherapy Testing Consortium (PCRTC) consists of specialized U01 research projects focused around the shared goal of testing of NCI-prioritized molecularly targeted anti-cancer agents from the CTEP collection (https://ctep.cancer.gov/) that best sensitize tumor cells to standard of care chemoradiation therapies. PCRTC teams were funded through PAR 16-111 To Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (https://grants.nih.gov/grants/guide/pa-files/par-16-111.html) to investigate NCI-supported investigational new drugs or agents (INDs) most likely to have clinical activity when combined with chemo-radiotherapy. These pre-clinical studies accelerate the pace at which combined modality treatments with greater efficacy are identified and incorporated into standard practices for treatments of patients with solid tumors, with concentration on cancers of the pancreas, lung, head and neck, gastrointestinal tract, and brain.

PCRTC Projects

Institution (primary site) MPI Contact Project Title
UNIVERSITY OF MICHIGAN AT ANN ARBOR THEODORE S. LAWRENCE Sensitization to Chemoradiation by Therapeutic Targeting of the DNA Damage Response
MASSACHUSETTS GENERAL HOSPITAL HENNING WILLERS High-Throughput Screening and Validation of Molecular Targeted Chemoradiosensitizerse
MAYO CLINIC ROCHESTER JANN N. SARKARIA Pre-Clinical Novel Radiosensitizer Evaluation Program for Brain Tumorse
UNIVERSITY OF TX MD ANDERSON CAN CTR STEVEN HSESHENG LIN Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches